SAN DIEGO, Jan. 3, 2019 /PRNewswire-PRWeb/ -- Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the founding of a scientific and medical advisory board (SMAB). The SMAB will enable Calidi Biotherapeutics to receive critical input…
Calidi BiotherapeuticsJanuary 3, 2019
SAN DIEGO, Nov. 6, 2018 -- Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of cell-delivered oncolytic viruses for the treatment of cancer, today announced that data from its clinical studies in late-stage cancer patients will be presented at the Society for Immunotherapy of Cancer…
Calidi BiotherapeuticsNovember 6, 2018
SAN DIEGO, October 25, 2018 - Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that it has been granted a new patent from the United States Patent Office (USPTO). Patent Number: 10,105,436 "Smallpox Vaccine for Cancer Treatment" covers the use…
Calidi BiotherapeuticsOctober 25, 2018
SAN DIEGO, May 24, 2018 -- Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced a focused effort to advance its oncolytic virus drug development. Calidi Biotherapeutics is developing a novel cell-based platform for delivery of oncolytic viruses, which…
Calidi BiotherapeuticsMay 24, 2018